## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

\_\_\_\_

## BEFORE THE PATENT TRIAL AND APPEAL BOARD

\_\_\_\_\_

APOTEX, INC. Petitioner,

v.

## UCB BIOPHARMA SPRL Patent Owner.

U.S. Patent No. 8,633,194 to Fanara *et al*.
Issue Date: January 21, 2014
Title: Pharmaceutical Composition of Piperazine Derivatives

Inter Partes Review No.: <u>IPR2019-00400</u>

**Notice of Stipulation to Extend Due Date 2** 

Mail Stop "PATENT BOARD"

Patent Trial and Appeal Board
U.S. Patent and Trademark Office

P.O. Box 1450 Alexandria, VA 22313-1450



Pursuant to the October 7, 2019 Scheduling Order (Paper 21), Petitioner hereby provides notice that Petitioner and Patent Owner have stipulated and agreed to extend Due Date 2 as shown below:

<b>Due Date</b>	<b>Current Date</b>	Revised Date
DUE DATE 2	January 14, 2020	January 16, 2020
Petitioner's reply to Patent Owner's response to the petition		
Petitioner's opposition to Patent Owner's motion to amend		

**DATED: 1/10/2020** 

Counsel of Record in IPR 2019-00400

Katten Muchin Rosenman LLP /Jitendra Malik / Jitendra Malik, Ph.D. Reg. No. 55,823 Counsel for Petitioner Apotex Inc. Fenwick & West LLP
/Robert E. Counihan/
Robert E. Counihan
Reg. No. 61,382
Counsel for Patent Owner UCB
Biopharma Sprl

